OpGen, Inc.
OpGen, Inc. OPGN Peers
See (OPGN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OPGN | $4.40 | -11.29% | 44.3M | -0.28 | -$15.53 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.56% |
| TMO | $402.71 | -3.04% | 152B | 23.29 | $17.29 | +0.50% |
| DHR | $200.59 | -2.20% | 143.6B | 38.87 | $5.16 | +0.56% |
| IDXX | $522.70 | -0.80% | 42B | 48.22 | $10.84 | N/A |
| A | $117.03 | -1.58% | 33.2B | 28.83 | $4.06 | +0.82% |
| IQV | $156.84 | -1.44% | 27.1B | 21.37 | $7.34 | N/A |
| MTD | $1,154.53 | -2.83% | 24B | 28.83 | $40.05 | N/A |
| NTRA | $165.34 | +0.60% | 22.6B | -111.72 | -$1.48 | N/A |
| WAT | $342.26 | -2.09% | 20.4B | 31.09 | $11.01 | N/A |
Stock Comparison
OPGN vs DHR-PB Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, OPGN is priced at $4.40, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, OPGN's ROE is +1.20%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, OPGN is less volatile compared to DHR-PB. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs TMO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, TMO has a market cap of 152B. Regarding current trading prices, OPGN is priced at $4.40, while TMO trades at $402.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas TMO's P/E ratio is 23.29. In terms of profitability, OPGN's ROE is +1.20%, compared to TMO's ROE of +0.13%. Regarding short-term risk, OPGN is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs DHR Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, DHR has a market cap of 143.6B. Regarding current trading prices, OPGN is priced at $4.40, while DHR trades at $200.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas DHR's P/E ratio is 38.87. In terms of profitability, OPGN's ROE is +1.20%, compared to DHR's ROE of +0.07%. Regarding short-term risk, OPGN is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs IDXX Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, IDXX has a market cap of 42B. Regarding current trading prices, OPGN is priced at $4.40, while IDXX trades at $522.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas IDXX's P/E ratio is 48.22. In terms of profitability, OPGN's ROE is +1.20%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, OPGN is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs A Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, A has a market cap of 33.2B. Regarding current trading prices, OPGN is priced at $4.40, while A trades at $117.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas A's P/E ratio is 28.83. In terms of profitability, OPGN's ROE is +1.20%, compared to A's ROE of +0.19%. Regarding short-term risk, OPGN is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs IQV Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, IQV has a market cap of 27.1B. Regarding current trading prices, OPGN is priced at $4.40, while IQV trades at $156.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas IQV's P/E ratio is 21.37. In terms of profitability, OPGN's ROE is +1.20%, compared to IQV's ROE of +0.21%. Regarding short-term risk, OPGN is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs MTD Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, MTD has a market cap of 24B. Regarding current trading prices, OPGN is priced at $4.40, while MTD trades at $1,154.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas MTD's P/E ratio is 28.83. In terms of profitability, OPGN's ROE is +1.20%, compared to MTD's ROE of +1.21%. Regarding short-term risk, OPGN is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs NTRA Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, NTRA has a market cap of 22.6B. Regarding current trading prices, OPGN is priced at $4.40, while NTRA trades at $165.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas NTRA's P/E ratio is -111.72. In terms of profitability, OPGN's ROE is +1.20%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, OPGN is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs WAT Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, WAT has a market cap of 20.4B. Regarding current trading prices, OPGN is priced at $4.40, while WAT trades at $342.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas WAT's P/E ratio is 31.09. In terms of profitability, OPGN's ROE is +1.20%, compared to WAT's ROE of +0.39%. Regarding short-term risk, OPGN is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs DGX Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, DGX has a market cap of 20.1B. Regarding current trading prices, OPGN is priced at $4.40, while DGX trades at $180.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas DGX's P/E ratio is 22.75. In terms of profitability, OPGN's ROE is +1.20%, compared to DGX's ROE of +0.13%. Regarding short-term risk, OPGN is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs PKI Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, OPGN is priced at $4.40, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas PKI's P/E ratio is 41.45. In terms of profitability, OPGN's ROE is +1.20%, compared to PKI's ROE of +0.04%. Regarding short-term risk, OPGN is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs ILMN Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ILMN has a market cap of 13.8B. Regarding current trading prices, OPGN is priced at $4.40, while ILMN trades at $86.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ILMN's P/E ratio is -14.30. In terms of profitability, OPGN's ROE is +1.20%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, OPGN is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs TEM Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, TEM has a market cap of 12B. Regarding current trading prices, OPGN is priced at $4.40, while TEM trades at $71.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas TEM's P/E ratio is -13.82. In terms of profitability, OPGN's ROE is +1.20%, compared to TEM's ROE of -5.31%. Regarding short-term risk, OPGN is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs ICLR Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ICLR has a market cap of 11.8B. Regarding current trading prices, OPGN is priced at $4.40, while ICLR trades at $145.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ICLR's P/E ratio is 15.87. In terms of profitability, OPGN's ROE is +1.20%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, OPGN is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs RVTY Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, RVTY has a market cap of 11B. Regarding current trading prices, OPGN is priced at $4.40, while RVTY trades at $93.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas RVTY's P/E ratio is 38.65. In terms of profitability, OPGN's ROE is +1.20%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, OPGN is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs QGEN Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, QGEN has a market cap of 10.2B. Regarding current trading prices, OPGN is priced at $4.40, while QGEN trades at $47.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas QGEN's P/E ratio is 109.58. In terms of profitability, OPGN's ROE is +1.20%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, OPGN is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs EXAS Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, EXAS has a market cap of 10.1B. Regarding current trading prices, OPGN is priced at $4.40, while EXAS trades at $53.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas EXAS's P/E ratio is -9.68. In terms of profitability, OPGN's ROE is +1.20%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, OPGN is less volatile compared to EXAS. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs MEDP Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, MEDP has a market cap of 8.6B. Regarding current trading prices, OPGN is priced at $4.40, while MEDP trades at $298.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas MEDP's P/E ratio is 22.22. In terms of profitability, OPGN's ROE is +1.20%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, OPGN is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs CRL Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, CRL has a market cap of 7.3B. Regarding current trading prices, OPGN is priced at $4.40, while CRL trades at $149.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas CRL's P/E ratio is -249.28. In terms of profitability, OPGN's ROE is +1.20%, compared to CRL's ROE of -0.01%. Regarding short-term risk, OPGN is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs GH Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, GH has a market cap of 6.1B. Regarding current trading prices, OPGN is priced at $4.40, while GH trades at $49.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas GH's P/E ratio is -14.54. In terms of profitability, OPGN's ROE is +1.20%, compared to GH's ROE of +3.69%. Regarding short-term risk, OPGN is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs SYNH Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, OPGN is priced at $4.40, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas SYNH's P/E ratio is 61.40. In terms of profitability, OPGN's ROE is +1.20%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, OPGN is less volatile compared to SYNH. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs RDNT Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, RDNT has a market cap of 4.2B. Regarding current trading prices, OPGN is priced at $4.40, while RDNT trades at $55.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas RDNT's P/E ratio is -128.86. In terms of profitability, OPGN's ROE is +1.20%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, OPGN is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs OLK Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, OPGN is priced at $4.40, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas OLK's P/E ratio is -96.59. In terms of profitability, OPGN's ROE is +1.20%, compared to OLK's ROE of -0.05%. Regarding short-term risk, OPGN is less volatile compared to OLK. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs SHC Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, SHC has a market cap of 3.2B. Regarding current trading prices, OPGN is priced at $4.40, while SHC trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas SHC's P/E ratio is 126.89. In terms of profitability, OPGN's ROE is +1.20%, compared to SHC's ROE of +0.06%. Regarding short-term risk, OPGN is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs TWST Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, TWST has a market cap of 2B. Regarding current trading prices, OPGN is priced at $4.40, while TWST trades at $33.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas TWST's P/E ratio is -10.31. In terms of profitability, OPGN's ROE is +1.20%, compared to TWST's ROE of -0.41%. Regarding short-term risk, OPGN is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs VIVO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, OPGN is priced at $4.40, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas VIVO's P/E ratio is 21.09. In terms of profitability, OPGN's ROE is +1.20%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, OPGN is less volatile compared to VIVO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs GRAL Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, GRAL has a market cap of 1.5B. Regarding current trading prices, OPGN is priced at $4.40, while GRAL trades at $41.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas GRAL's P/E ratio is -0.69. In terms of profitability, OPGN's ROE is +1.20%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, OPGN is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs NEOG Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, NEOG has a market cap of 1.2B. Regarding current trading prices, OPGN is priced at $4.40, while NEOG trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas NEOG's P/E ratio is -2.48. In terms of profitability, OPGN's ROE is +1.20%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, OPGN is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs OPK Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, OPGN is priced at $4.40, while OPK trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas OPK's P/E ratio is -22.25. In terms of profitability, OPGN's ROE is +1.20%, compared to OPK's ROE of -0.03%. Regarding short-term risk, OPGN is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs CDNA Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, CDNA has a market cap of 1B. Regarding current trading prices, OPGN is priced at $4.40, while CDNA trades at $18.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas CDNA's P/E ratio is 16.60. In terms of profitability, OPGN's ROE is +1.20%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, OPGN is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs FLGT Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, FLGT has a market cap of 629.3M. Regarding current trading prices, OPGN is priced at $4.40, while FLGT trades at $20.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas FLGT's P/E ratio is -15.54. In terms of profitability, OPGN's ROE is +1.20%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, OPGN is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs GRALV Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, OPGN is priced at $4.40, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas GRALV's P/E ratio is N/A. In terms of profitability, OPGN's ROE is +1.20%, compared to GRALV's ROE of N/A. Regarding short-term risk, OPGN is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs CSTL Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, CSTL has a market cap of 541.9M. Regarding current trading prices, OPGN is priced at $4.40, while CSTL trades at $18.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas CSTL's P/E ratio is -98.79. In terms of profitability, OPGN's ROE is +1.20%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, OPGN is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs PSNL Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, PSNL has a market cap of 529.1M. Regarding current trading prices, OPGN is priced at $4.40, while PSNL trades at $5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas PSNL's P/E ratio is -4.64. In terms of profitability, OPGN's ROE is +1.20%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, OPGN is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs MYGN Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, MYGN has a market cap of 463.7M. Regarding current trading prices, OPGN is priced at $4.40, while MYGN trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas MYGN's P/E ratio is -4.49. In terms of profitability, OPGN's ROE is +1.20%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, OPGN is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs CO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, OPGN is priced at $4.40, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas CO's P/E ratio is 5.06. In terms of profitability, OPGN's ROE is +1.20%, compared to CO's ROE of +0.11%. Regarding short-term risk, OPGN is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs LAB Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, LAB has a market cap of 398.8M. Regarding current trading prices, OPGN is priced at $4.40, while LAB trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas LAB's P/E ratio is -3.28. In terms of profitability, OPGN's ROE is +1.20%, compared to LAB's ROE of -0.28%. Regarding short-term risk, OPGN is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs FLDM Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, OPGN is priced at $4.40, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas FLDM's P/E ratio is -4.74. In terms of profitability, OPGN's ROE is +1.20%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, OPGN is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs STIM Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, STIM has a market cap of 249.5M. Regarding current trading prices, OPGN is priced at $4.40, while STIM trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas STIM's P/E ratio is -2.87. In terms of profitability, OPGN's ROE is +1.20%, compared to STIM's ROE of -2.09%. Regarding short-term risk, OPGN is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs NEO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, NEO has a market cap of 182M. Regarding current trading prices, OPGN is priced at $4.40, while NEO trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas NEO's P/E ratio is -11.59. In terms of profitability, OPGN's ROE is +1.20%, compared to NEO's ROE of -0.09%. Regarding short-term risk, OPGN is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs ACRS Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ACRS has a market cap of 160.3M. Regarding current trading prices, OPGN is priced at $4.40, while ACRS trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ACRS's P/E ratio is -0.93. In terms of profitability, OPGN's ROE is +1.20%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, OPGN is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs XGN Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, XGN has a market cap of 155.6M. Regarding current trading prices, OPGN is priced at $4.40, while XGN trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas XGN's P/E ratio is -8.38. In terms of profitability, OPGN's ROE is +1.20%, compared to XGN's ROE of -1.34%. Regarding short-term risk, OPGN is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs ATLN Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ATLN has a market cap of 144.2M. Regarding current trading prices, OPGN is priced at $4.40, while ATLN trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ATLN's P/E ratio is -0.67. In terms of profitability, OPGN's ROE is +1.20%, compared to ATLN's ROE of -19.68%. Regarding short-term risk, OPGN is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs GTH Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, OPGN is priced at $4.40, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas GTH's P/E ratio is -1.11. In terms of profitability, OPGN's ROE is +1.20%, compared to GTH's ROE of -1.01%. Regarding short-term risk, OPGN is less volatile compared to GTH. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs PRENW Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, PRENW has a market cap of 122.9M. Regarding current trading prices, OPGN is priced at $4.40, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas PRENW's P/E ratio is N/A. In terms of profitability, OPGN's ROE is +1.20%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, OPGN is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs GENE Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, OPGN is priced at $4.40, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas GENE's P/E ratio is -38.25. In terms of profitability, OPGN's ROE is +1.20%, compared to GENE's ROE of -3.62%. Regarding short-term risk, OPGN and GENE have similar daily volatility (0.00).
OPGN vs MDXH Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, MDXH has a market cap of 99M. Regarding current trading prices, OPGN is priced at $4.40, while MDXH trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas MDXH's P/E ratio is -1.92. In terms of profitability, OPGN's ROE is +1.20%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, OPGN is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs PRE Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, PRE has a market cap of 91.6M. Regarding current trading prices, OPGN is priced at $4.40, while PRE trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas PRE's P/E ratio is -1.89. In terms of profitability, OPGN's ROE is +1.20%, compared to PRE's ROE of -0.25%. Regarding short-term risk, OPGN is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs NOTV Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, NOTV has a market cap of 76.3M. Regarding current trading prices, OPGN is priced at $4.40, while NOTV trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas NOTV's P/E ratio is -0.71. In terms of profitability, OPGN's ROE is +1.20%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, OPGN is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs VNRX Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, VNRX has a market cap of 65.5M. Regarding current trading prices, OPGN is priced at $4.40, while VNRX trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas VNRX's P/E ratio is -2.35. In terms of profitability, OPGN's ROE is +1.20%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, OPGN is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs SERA Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, SERA has a market cap of 62.8M. Regarding current trading prices, OPGN is priced at $4.40, while SERA trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas SERA's P/E ratio is -1.82. In terms of profitability, OPGN's ROE is +1.20%, compared to SERA's ROE of -0.51%. Regarding short-term risk, OPGN is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs BDSX Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, BDSX has a market cap of 41.6M. Regarding current trading prices, OPGN is priced at $4.40, while BDSX trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas BDSX's P/E ratio is -1.05. In terms of profitability, OPGN's ROE is +1.20%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, OPGN is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs DRIO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, DRIO has a market cap of 29.6M. Regarding current trading prices, OPGN is priced at $4.40, while DRIO trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas DRIO's P/E ratio is -1.21. In terms of profitability, OPGN's ROE is +1.20%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, OPGN is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs STRRP Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, STRRP has a market cap of 29.2M. Regarding current trading prices, OPGN is priced at $4.40, while STRRP trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas STRRP's P/E ratio is -4.56. In terms of profitability, OPGN's ROE is +1.20%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, OPGN is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs AKU Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, OPGN is priced at $4.40, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas AKU's P/E ratio is -0.13. In terms of profitability, OPGN's ROE is +1.20%, compared to AKU's ROE of -5.32%. Regarding short-term risk, OPGN is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs ADVB Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ADVB has a market cap of 20.4M. Regarding current trading prices, OPGN is priced at $4.40, while ADVB trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ADVB's P/E ratio is -5.88. In terms of profitability, OPGN's ROE is +1.20%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, OPGN is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs CEMI Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, OPGN is priced at $4.40, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas CEMI's P/E ratio is -0.63. In terms of profitability, OPGN's ROE is +1.20%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, OPGN and CEMI have similar daily volatility (0.00).
OPGN vs ENZ Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, OPGN is priced at $4.40, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ENZ's P/E ratio is -2.24. In terms of profitability, OPGN's ROE is +1.20%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, OPGN is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs PRPO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, PRPO has a market cap of 16.4M. Regarding current trading prices, OPGN is priced at $4.40, while PRPO trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas PRPO's P/E ratio is -5.42. In terms of profitability, OPGN's ROE is +1.20%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, OPGN is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs PMD Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, OPGN is priced at $4.40, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas PMD's P/E ratio is -5.24. In terms of profitability, OPGN's ROE is +1.20%, compared to PMD's ROE of -0.33%. Regarding short-term risk, OPGN is less volatile compared to PMD. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs ME Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, OPGN is priced at $4.40, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ME's P/E ratio is -0.03. In terms of profitability, OPGN's ROE is +1.20%, compared to ME's ROE of -3.10%. Regarding short-term risk, OPGN is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs INBS Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, INBS has a market cap of 13.1M. Regarding current trading prices, OPGN is priced at $4.40, while INBS trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas INBS's P/E ratio is -1.43. In terms of profitability, OPGN's ROE is +1.20%, compared to INBS's ROE of -1.72%. Regarding short-term risk, OPGN is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs BNGO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, BNGO has a market cap of 12.1M. Regarding current trading prices, OPGN is priced at $4.40, while BNGO trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas BNGO's P/E ratio is -0.07. In terms of profitability, OPGN's ROE is +1.20%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, OPGN is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs TRIB Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, TRIB has a market cap of 12.1M. Regarding current trading prices, OPGN is priced at $4.40, while TRIB trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas TRIB's P/E ratio is -0.36. In terms of profitability, OPGN's ROE is +1.20%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, OPGN is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs CNTG Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, OPGN is priced at $4.40, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas CNTG's P/E ratio is -0.23. In terms of profitability, OPGN's ROE is +1.20%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, OPGN is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs BIAFW Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, BIAFW has a market cap of 8.5M. Regarding current trading prices, OPGN is priced at $4.40, while BIAFW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas BIAFW's P/E ratio is N/A. In terms of profitability, OPGN's ROE is +1.20%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, OPGN and BIAFW have similar daily volatility (0.00).
OPGN vs BIAF Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, BIAF has a market cap of 7.8M. Regarding current trading prices, OPGN is priced at $4.40, while BIAF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas BIAF's P/E ratio is -0.39. In terms of profitability, OPGN's ROE is +1.20%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, OPGN is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs MYNZ Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, MYNZ has a market cap of 7M. Regarding current trading prices, OPGN is priced at $4.40, while MYNZ trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas MYNZ's P/E ratio is -0.08. In terms of profitability, OPGN's ROE is +1.20%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, OPGN is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs STRR Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, STRR has a market cap of 6.4M. Regarding current trading prices, OPGN is priced at $4.40, while STRR trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas STRR's P/E ratio is -0.66. In terms of profitability, OPGN's ROE is +1.20%, compared to STRR's ROE of -0.24%. Regarding short-term risk, OPGN is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs NVTA Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, OPGN is priced at $4.40, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas NVTA's P/E ratio is -0.00. In terms of profitability, OPGN's ROE is +1.20%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, OPGN is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs LMDX Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, OPGN is priced at $4.40, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas LMDX's P/E ratio is -0.01. In terms of profitability, OPGN's ROE is +1.20%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, OPGN is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs LMDXW Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, OPGN is priced at $4.40, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, OPGN's ROE is +1.20%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, OPGN is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs BGLC Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, BGLC has a market cap of 4.9M. Regarding current trading prices, OPGN is priced at $4.40, while BGLC trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas BGLC's P/E ratio is -2.31. In terms of profitability, OPGN's ROE is +1.20%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, OPGN is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs CHEK Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, CHEK has a market cap of 4.4M. Regarding current trading prices, OPGN is priced at $4.40, while CHEK trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas CHEK's P/E ratio is -0.35. In terms of profitability, OPGN's ROE is +1.20%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, OPGN is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs TTOO Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, TTOO has a market cap of 3.9M. Regarding current trading prices, OPGN is priced at $4.40, while TTOO trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas TTOO's P/E ratio is -4.67. In terms of profitability, OPGN's ROE is +1.20%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, OPGN is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs BNR Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, BNR has a market cap of 3.8M. Regarding current trading prices, OPGN is priced at $4.40, while BNR trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas BNR's P/E ratio is -1.11. In terms of profitability, OPGN's ROE is +1.20%, compared to BNR's ROE of -0.53%. Regarding short-term risk, OPGN is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs DMTK Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, OPGN is priced at $4.40, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas DMTK's P/E ratio is -0.04. In terms of profitability, OPGN's ROE is +1.20%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, OPGN is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs AWH Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, OPGN is priced at $4.40, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas AWH's P/E ratio is -0.09. In terms of profitability, OPGN's ROE is +1.20%, compared to AWH's ROE of +4.66%. Regarding short-term risk, OPGN is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs ISPC Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, ISPC has a market cap of 2.6M. Regarding current trading prices, OPGN is priced at $4.40, while ISPC trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas ISPC's P/E ratio is -0.09. In terms of profitability, OPGN's ROE is +1.20%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, OPGN is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs NDRA Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, NDRA has a market cap of 2.6M. Regarding current trading prices, OPGN is priced at $4.40, while NDRA trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas NDRA's P/E ratio is 0.01. In terms of profitability, OPGN's ROE is +1.20%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, OPGN is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs SQL Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, OPGN is priced at $4.40, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas SQL's P/E ratio is -0.40. In terms of profitability, OPGN's ROE is +1.20%, compared to SQL's ROE of +10.89%. Regarding short-term risk, OPGN is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs APDN Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, APDN has a market cap of 2.4M. Regarding current trading prices, OPGN is priced at $4.40, while APDN trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas APDN's P/E ratio is N/A. In terms of profitability, OPGN's ROE is +1.20%, compared to APDN's ROE of -2.81%. Regarding short-term risk, OPGN is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs HTGM Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, OPGN is priced at $4.40, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas HTGM's P/E ratio is -0.03. In terms of profitability, OPGN's ROE is +1.20%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, OPGN and HTGM have similar daily volatility (0.00).
OPGN vs SQLLW Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, SQLLW has a market cap of 871.8K. Regarding current trading prices, OPGN is priced at $4.40, while SQLLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas SQLLW's P/E ratio is -0.04. In terms of profitability, OPGN's ROE is +1.20%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, OPGN is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs BIOC Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, OPGN is priced at $4.40, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas BIOC's P/E ratio is -0.01. In terms of profitability, OPGN's ROE is +1.20%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, OPGN is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs DHR-PA Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, OPGN is priced at $4.40, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, OPGN's ROE is +1.20%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, OPGN is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs MEUSW Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, OPGN is priced at $4.40, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas MEUSW's P/E ratio is N/A. In terms of profitability, OPGN's ROE is +1.20%, compared to MEUSW's ROE of -3.10%. Regarding short-term risk, OPGN is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.
OPGN vs OCDX Comparison
OPGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPGN stands at 44.3M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, OPGN is priced at $4.40, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPGN currently has a P/E ratio of -0.28, whereas OCDX's P/E ratio is -42.28. In terms of profitability, OPGN's ROE is +1.20%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, OPGN is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for OPGN.